ArticlePloS one2026
Plasma lipidomics, choline metabolites, and metabolic-associated steatotic liver disease (MASLD): A Coronary Artery Risk Development in Young Adults (CARDIA) study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Metabolic-associated steatotic liver disease (MASLD) is marked by accumulation of hepatic triacylglycerols (TAG), but many other lipids have been implicated. Choline metabolism has been shown to be related to MASLD, specifically through phosphatidylcholines (PC) role in hepatic TAG removal through very low density lipoproteins (VLDL). There are a lack of population-based studies with integrated data on lipidomics, choline metabolites, and MASLD. We tested associations between the plasma lipidome, choline metabolites, and MASLD using data from the Coronary Artery Risk Development in Young Adults (CARDIA) Study. The analytic sample included 1,039 participants with data on choline metabolite, lipidomic, and liver attenuation data [mean (SD) age: 45 (4); 57% female; 57% White race]. MASLD (n = 234) was defined as mean CT-derived liver attenuation < 51HU. Plasma lipidomics and choline metabolites were quantified from stored fasting plasma using liquid-chromatography and infusion-mass spectrometry. In logistic regression adjusted for sociodemographics, lifestyle, and clinical variables, total TAGs, diacylglycerols (DAG), and dihydroceramides (DCER) were positively, and lactosylceramides (LCER) were inversely, associated with MASLD. Species-level results revealed diverging MASLD associations for PCs, based on FA composition. In choline metabolite models, betaine was inversely associated with MASLD. A lipidomic risk score (LRS) derived from penalized regression of MASLD on lipid species was associated positively with choline, and inversely with betaine. We contribute population-based results to a growing literature relating lipidomics and MASLD. In our data, FA composition is biologically relevant to MASLD, particularly for PCs and TAGs. Our results link choline metabolites to both the plasma lipidome and to incident MASLD, furthering efforts in biomarker development and supporting mechanistic evidence using population-level data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.